Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zerenex in ESRD patients on dialysis
NCT01191255Phase 3Completed
- Sponsor
- Keryx Biopharmaceuticals, Inc.
- Start
- Oct 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ferric citrate in hyperphosphatemia (3 arms), sponsored by Keryx Biopharmaceuticals, Inc. Primary endpoint: Change in Mean Serum Phosphorus at 4 weeks. Started Oct 2010; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01191255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191255.